Phage display represents an attractive screening strategy for the identification of novel, specific binding ligands that could be used for tumor targeting. Recently, a new peptide (CaIX-P1) with affinity for human carbonic anhydrase IX (CAIX) was identified and evaluated. The aim of the present study is to characterize the properties of CaIX-P1 for targeting human colorectal carcinoma and investigate the correlation of peptide binding with the expression of carbonic anhydrase IX. Human colorectal carcinoma HCT116 and HT29 cells were investigated for CAIX expression using Western Blot analysis. Binding and competition studies of 125I-radiolabeled CaIX-P1 were performed on HCT116 cells in vitro. FACS analysis and fluorescence microscopy studies were carried out after cell incubation with fluorescein-labeled CaIX-P1 and rhodamine-labeled anti-human CAIX-mAb. Our studies revealed an enhanced in vitro expression of carbonic anhydrase IX in HCT116 and HT29 cells with increasing cell density. Binding of 125I-labeled-CaIX-P1 on HCT116 cells increased with increasing cell density and correlated to the CAIX expression. FACS analysis demonstrated a correlation of cell labeling between FITC-CaIX-P1 and rhodamine-labeled anti-CAIX-mAb in both HCT116 and HT29 cells. The results of our study indicate that the phage display identified peptide CaIX-P1 might be an attractive candidate for the development of a ligand targeting CAIX in colorectal cancer.
References
[1]
Winum, J.Y.; Rami, M.; Scozzafava, A.; Montero, J.L.; Supuran, C. Carbonic anhydrase IX: A new druggable target for the design of antitumor agents. Med. Res. Rev 2008, 28, 445–463.
[2]
Grabmaier, K.; A de Weijert, M.C.; Verhaegh, G.W.; Schalken, J.A.; Oosterwijk, E. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 2004, 23, 5624–5631.
[3]
Pinheiro, C.; Sousa, B.; Albergaria, A.; Paredes, J.; Dufloth, R.; Vieira, D.; Schmitt, F.; Baltazar, F. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol. Histopathol 2011, 26, 1279–1286.
[4]
Vaupel, P.; Mayer, A. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26, 225–239.
[5]
Neri, D.; Supuran, C.T. Interfering with pH regulation in tumours as a therapeutic strategy. Nat. Rev. Drug Discov 2011, 10, 767–777.
[6]
Supuran, C.T.; Winum, J.Y. Drug Design of Zinc-Enzyme Inhibitors–Functional, Structural, and Disease Applications; Wang, B., Ed.; John Wiley & Sons, Inc: Hoboken, NJ, USA, 2009.
[7]
Supuran, C.T. Inhibition of carbonic anhydrase IX as a novel anticancer mechanism. World J. Clin. Oncol 2012, 3, 98–103.
[8]
Dubois, L.; Lieuwes, N.G.; Maresca, A.; Thiry, A.; Supuran, C.T.; Scozzafava, A.; Wouters, B.G.; Lambin, P. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother. Oncol 2009, 92, 423–428.
[9]
Ahlskog, J.K.; Dumelin, C.E.; Trüssel, S.; M？rlind, J.; Neri, D. In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg. Med. Chem. Lett 2009, 19, 4851–4856.
[10]
Li, J.; Shi, L.; Wang, C.; Zhang, X.; Jia, L.; Li, X.; Zhou, W.; Qi, Y.; Zhang, L. Preliminary biological evaluation of 125I-labeled anti-carbonic anhydrase IX monoclonal antibody in the mice bearing HAT-29 tumors. Nucl. Med. Commun 2011, 32, 1190–1193.
[11]
Wu, A.M.; Senter, P.D. Arming antibodies: Prospects and challenges for immunoconjugates. Nat. Biotechnol 2005, 23, 1137–1146.
[12]
Haberkorn, U.; Eisenhut, M.; Altmann, A.; Mier, W. Endoradiotherapy with peptides-status and future development. Curr. Med. Chem 2008, 15, 219–234.
[13]
Marr, A.; Markert, A.; Altmann, A.; Askoxylakis, V.; Haberkorn, U. Biotechnology techniques for the development of new tumor specific peptides. Methods 2011, 55, 215–222.
[14]
Askoxylakis, V.; Garcia-Boy, R.; Rana, S.; Kr？mer, S.; Hebling, U.; Mier, W.; Altmann, A.; Markert, A.; Debus, J.; Haberkorn, U. A new peptide ligand for targeting human carbonic anhydrase IX, identified through the phage display technology. PLoS One 2010, 5, e15962.
[15]
Sansone, P.; Piazzi, G.; Paterini, P.; Strillacci, A.; Ceccarelli, C.; Minni, F.; Biasco, G.; Chieco, P.; Bonafé, M. Cyclooxygenase-2/carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cells. J. Cell. Mol. Med 2009, 13, 3876–3887.
[16]
Hunakova, L.; Bodo, J.; Chovancova, J.; Sulikova, G.; Pastorekova, S.; Sedlak, J. Expression of new prognostic markers, peripheral-type benzodiazepine receptor and carbonic anhydrase IX, in human breast and ovarian carcinoma cell lines. Neoplasma 2007, 54, 541–548.
[17]
Askoxylakis, V.; Millonig, G.; Wirkner, U.; Schwager, C.; Rana, S.; Altmann, A.; Haberkorn, U.; Debus, J.; Mueller, S.; Huber, P.E. Investigation of tumor hypoxia using a two-enzyme system for in vitro generation of oxygen deficiency. Radiat. Oncol 2011, 6, 35.
[18]
Kaluz, S.; Kaluzová, M.; Chrastina, A.; Olive, P.L.; Pastoreková, S.; Pastorek, J.; Lerman, M.I.; Stanbridge, E.J. Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: A role for phosphatidylinositol 3′-kinase. Cancer Res 2002, 62, 4469–4477.
[19]
Nothelfer, E.M.; Zitzmann-Kolbe, S.; Garcia-Boy, R.; Kr？mer, S.; Herold-Mende, C.; Altmann, A.; Eisenhut, M.; Mier, W.; Haberkorn, U. Identification and characterization of a peptide with affinity to head and neck cancer. J. Nucl. Med 2009, 50, 426–434.
[20]
Zhang, J.; Spring, H.; Schwab, M. Neuroblastoma tumor cell-binding peptides identified through random peptide phage display. Cancer Lett 2001, 171, 153–164.
[21]
Di Cianni, A.; Carotenuto, A.; Brancaccio, D.; Novellino, E.; Reubi, J.C.; Beetschen, K.; Papini, A.M.; Ginanneschi, M. Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J. Med. Chem 2010, 53, 6188–6197.
[22]
Liu, S.; Liu, Z.; Chen, K.; Yan, Y.; Watzlowik, P.; Wester, H.J.; Chin, F.T.; Chen, X. 18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol. Imaging Biol 2010, 12, 530–538.
Rana, S.; Nissen, F.; Marr, A.; Markert, A.; Altmann, A.; Mier, W.; Debus, J.; Haberkorn, U.; Askoxylakis, V. Optimization of a novel peptide ligand targeting human carbonic anhydrase IX. PLoS One 2012, 7, e38279.
[25]
Hilpert, K.; Winkler, D.F.; Hancock, R.E. Peptide arrays on cellulose support: SPOT synthesis, a time and cost efficient method for synthesis of large numbers of peptides in a parallel and addressable fashion. Nat. Protoc 2007, 2, 1333–1349.
[26]
Winkler, D.F.; Hilpert, K.; Brandt, O.; Hancock, R.E. Synthesis of peptide arrays using SPOT technology and the CelluSpots-method. Methods Mol. Biol 2009, 570, 157–174.
[27]
Ahmed, S.; Mathews, A.S.; Byeon, N.; Lavasanifar, A.; Kaur, K. Peptide arrays for screening cancer specific peptides. Anal. Chem 2010, 82, 7533–7541.
[28]
Zoller, F.; Haberkorn, U.; Mier, W. Miniproteins as phage display-scaffolds for clinical applications. Molecules 2011, 16, 2467–2485.
[29]
John, H.; Maronde, E.; Forssmann, W.G.; Meyer, M.; Adermann, K. N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity. Eur. J. Med. Res 2008, 13, 73–78.
[30]
Gentilucci, L.; de Marco, R.; Cerisoli, L. Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr. Pharm. Des 2010, 16, 3185–3203.
[31]
Askoxylakis, V.; Zitzmann-Kolbe, S.; Zoller, F.; Altmann, A.; Markert, A.; Rana, S.; Marr, A.; Mier, W.; Debus, J.; Haberkorn, U. Challenges in optimizing a prostate carcinoma binding peptide, identified through the phage display technology. Molecules 2011, 16, 1559–1578.
[32]
Aloj, L.; Morelli, G. Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapy. Curr. Pharm. Des 2004, 10, 3009–3031.
[33]
Pnwar, P.; Iznaga-Escobar, N.; Mishra, P.; Srivastava, V.; Sharma, R.K.; Chandra, R.; Mishra, A.K. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy. Cancer Biol. Ther 2005, 4, 854–860.
